Please login to the form below

Not currently logged in
Email:
Password:

BMS hires Roche's Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

Mike Burgess, BMSMike Burgess has left Roche to become senior VP, discovery medicine and clinical pharmacology at Bristol-Myers Squibb.

Most recently, he was interim head of research and early development at Roche - a position now occupied by John Reed - and had previously led the Swiss pharma firm's oncology discovery and translational area at the same time as serving as head of global large molecule research.

In his new role, he will report to Dr Francis Cuss, senior VP research, R&D, and will be a member of BMS's research senior leadership team.

“As a physician scientist with a PhD in molecular biology, clinical experience in paediatrics and paediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organisation,” said Dr Cuss.

“Mike's broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”

Prior to joining Roche, Dr Burgess was a medical fellow at Lilly, having completed his PhD at the University of Bristol in the UK.

21st January 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics